Get startedLog in
    Picture of Tenaya Therapeutics logo

    TNYA — Tenaya Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027

    Picture of Tenaya Therapeutics logoTenaya Therapeutics
    11/03/2026 20:37
    Overview

US cardiac gene therapy developer's Q4 net loss narrowed to $20.18 mln, compared to analysts' expectations of a loss of $22.05 mln

Q4 operating loss was lower than expected

Company closed $55.8 mln financing and entered into research collaboration with Alnylam deal, extending cash runway into H2 2027

Outlook

Tenaya expects to report interim and longer-term TN-201 clinical trial data throughout 2026

Company plans to advance TN-301 toward clinical trials in patients in 2026

Tenaya expects cash resources to fund operations into second half of 2027

Result Drivers

LOWER R&D SPENDING - Q4 R&D expenses fell to $14.8 mln from $18.7 mln a year earlier

PIPELINE PROGRESS - Co reported promising interim clinical data for TN-201 and TN-401 gene therapy programs and new preclinical data for TN-301

COST CONTROL - G&A expenses were flat year-over-year at $6.0 mln in Q4

Company press release: ID:nGNX2HJFNl

Key Details


    MetricBeat/MissActualConsensus Estimate
    Q4 Net IncomeBeat-$20.18 mln-$22.05 mln (4 Analysts)
    Q4 Operating IncomeBeat-$20.78 mln-$22.40 mln (3 Analysts)
    Q4 Pretax ProfitBeat-$20.18 mln-$22.05 mln (4 Analysts)
    Q4 Basic EPS-$0.12
    Q4 Operating Expenses$20.78 mln
    

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $3.00, about 235.2% above its March 10 closing price of $0.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

    Recent news on Tenaya Therapeutics

    See all news